141 related articles for article (PubMed ID: 29948147)
21. Saccharomyces cerevisiae-like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusion-positive and fusion-negative cancers.
Burdelski C; Barreau Y; Simon R; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Sauter G; Wittmer C; Steurer S; Adam M; Huland H; Schlomm T; Tsourlakis MC; Quaas A
Hum Pathol; 2015 Apr; 46(4):514-23. PubMed ID: 25701228
[TBL] [Abstract][Full Text] [Related]
22. The prognostic role of ERG immunopositivity in prostatic acinar adenocarcinoma: a study including 454 cases and review of the literature.
Xu B; Chevarie-Davis M; Chevalier S; Scarlata E; Zeizafoun N; Dragomir A; Tanguay S; Kassouf W; Aprikian A; Brimo F
Hum Pathol; 2014 Mar; 45(3):488-97. PubMed ID: 24406017
[TBL] [Abstract][Full Text] [Related]
23. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
Berg KD
Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
[TBL] [Abstract][Full Text] [Related]
24. [Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer].
Dai MJ; Chen LL; Zheng YB; Chen W; Tao ZH; Weng ZL; Wu XL; Li CD; Chen ZG; Chen XD; Shi SB
Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(10):669-73. PubMed ID: 18642766
[TBL] [Abstract][Full Text] [Related]
25. Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathologic features of prostate cancer.
Kron K; Liu L; Trudel D; Pethe V; Trachtenberg J; Fleshner N; Bapat B; van der Kwast T
Clin Cancer Res; 2012 May; 18(10):2896-904. PubMed ID: 22452941
[TBL] [Abstract][Full Text] [Related]
26. In situ sequencing identifies TMPRSS2-ERG fusion transcripts, somatic point mutations and gene expression levels in prostate cancers.
Kiflemariam S; Mignardi M; Ali MA; Bergh A; Nilsson M; Sjöblom T
J Pathol; 2014 Oct; 234(2):253-61. PubMed ID: 24931216
[TBL] [Abstract][Full Text] [Related]
27. Weaker ERG expression in patients with ERG-positive prostate cancer is associated with advanced disease and weaker androgen receptor expression: An Indian outlook.
Suryavanshi M; Mehta A; Jaipuria J; Sharma AK; Rawal S; Seth N
Urol Oncol; 2015 Jul; 33(7):331.e9-15. PubMed ID: 25899828
[TBL] [Abstract][Full Text] [Related]
28. TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer.
Steurer S; Mayer PS; Adam M; Krohn A; Koop C; Ospina-Klinck D; Tehrani AA; Simon R; Tennstedt P; Graefen M; Wittmer C; Brors B; Plass C; Korbel J; Weischenfeldt J; Sauter G; Huland H; Tsourlakis MC; Minner S; Schlomm T
Eur Urol; 2014 Dec; 66(6):978-81. PubMed ID: 25015038
[TBL] [Abstract][Full Text] [Related]
29. Phosphorylation of the oncogenic transcription factor ERG in prostate cells dissociates polycomb repressive complex 2, allowing target gene activation.
Kedage V; Strittmatter BG; Dausinas PB; Hollenhorst PC
J Biol Chem; 2017 Oct; 292(42):17225-17235. PubMed ID: 28887309
[TBL] [Abstract][Full Text] [Related]
30. Obesity and Prostate Cancer Risk According to Tumor TMPRSS2:ERG Gene Fusion Status.
Egbers L; Luedeke M; Rinckleb A; Kolb S; Wright JL; Maier C; Neuhouser ML; Stanford JL
Am J Epidemiol; 2015 May; 181(9):706-13. PubMed ID: 25852077
[TBL] [Abstract][Full Text] [Related]
31. A 36-gene signature predicts clinical progression in a subgroup of ERG-positive prostate cancers.
Gasi Tandefelt D; Boormans JL; van der Korput HA; Jenster GW; Trapman J
Eur Urol; 2013 Dec; 64(6):941-50. PubMed ID: 23490727
[TBL] [Abstract][Full Text] [Related]
32. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
[TBL] [Abstract][Full Text] [Related]
33. High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions.
Grupp K; Wilking J; Prien K; Hube-Magg C; Sirma H; Simon R; Steurer S; Budäus L; Haese A; Izbicki J; Sauter G; Minner S; Schlomm T; Tsourlakis MC
Eur J Cancer; 2014 Mar; 50(4):852-61. PubMed ID: 24380696
[TBL] [Abstract][Full Text] [Related]
34. Altered DNA methylation landscapes of polycomb-repressed loci are associated with prostate cancer progression and ERG oncogene expression in prostate cancer.
Kron K; Trudel D; Pethe V; Briollais L; Fleshner N; van der Kwast T; Bapat B
Clin Cancer Res; 2013 Jul; 19(13):3450-61. PubMed ID: 23549870
[TBL] [Abstract][Full Text] [Related]
35. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.
Winnes M; Lissbrant E; Damber JE; Stenman G
Oncol Rep; 2007 May; 17(5):1033-6. PubMed ID: 17390040
[TBL] [Abstract][Full Text] [Related]
36. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
[TBL] [Abstract][Full Text] [Related]
37. ERG protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer.
Berg KD; Vainer B; Thomsen FB; Røder MA; Gerds TA; Toft BG; Brasso K; Iversen P
Eur Urol; 2014 Nov; 66(5):851-60. PubMed ID: 24630684
[TBL] [Abstract][Full Text] [Related]
38. Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset.
Hernández S; Font-Tello A; Juanpere N; de Muga S; Lorenzo M; Salido M; Fumadó L; Serrano L; Cecchini L; Serrano S; Lloreta J
Prostate; 2016 Jun; 76(9):854-65. PubMed ID: 26959281
[TBL] [Abstract][Full Text] [Related]
39. Identification of novel oncogenic events occurring early in prostate carcinogenesis using purified autologous malignant and non-malignant prostate epithelial cells.
Sluka P; Pezaro C; Wardan H; Sengupta S; Davis ID
BJU Int; 2019 May; 123 Suppl 5():27-35. PubMed ID: 30712320
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer.
Rice KR; Chen Y; Ali A; Whitman EJ; Blase A; Ibrahim M; Elsamanoudi S; Brassell S; Furusato B; Stingle N; Sesterhenn IA; Petrovics G; Miick S; Rittenhouse H; Groskopf J; McLeod DG; Srivastava S
Clin Cancer Res; 2010 Mar; 16(5):1572-6. PubMed ID: 20160063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
